Notably, the proteasome inhibitor, MG132, restored Mcl-1 expression, suggesting that the degradation of Mcl-1 was enhanced in Skp2-null CRC cells (Fig. 4B). The gene discussed is MCL1; the disease is colorectal carcinoma.